 |
71 Diseases |  |
105 Trials |
|
105 Trials |  |
2830 News |  |
| «12345678910111213...3738» |
- Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
Overall survival with sacituzumab govitecan in hormone receptor- positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial () - Jan 22, 2024 - Abstract #YIR2024YIR_123;
P3
In this randomised, open-label, multicentre, phase 3 trial, which took place in 91 centres across North America (the USA and Canada) and Europe (Belgium, France, Germany, Italy, the Netherlands, Spain, and the UK), patients were randomly assigned (1:1) to receive sacituzumab govitecan or chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine). Sacituzumab govitecan demonstrated statistically significant and clinically meaningful benefit over chemotherapy, with a 3
- || Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Clinical data, P2 data, Journal, Metastases: Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft Tissue Sarcomas: Clinical Outcomes and Biological Correlates. (Pubmed Central) - Jan 18, 2024
Sacituzumab govitecan demonstrated statistically significant and clinically meaningful benefit over chemotherapy, with a 3 The combination of eribulin and pembrolizumab demonstrated promising activity in LPS and angiosarcoma.
- || Halaven (eribulin mesylate) / Eisai
P1/2 data, Journal, Combination therapy, Metastases: A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer. (Pubmed Central) - Jan 15, 2024
P1/2
The combination of eribulin and pembrolizumab demonstrated promising activity in LPS and angiosarcoma. In heavily pretreated patients with ABC, treatment with EC resulted in an encouraging CBR of 79.5% and PFS of 16.4
- || Trial completion date, IO biomarker, Metastases: SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Jan 11, 2024
P2, N=1460, Active, not recruiting, Sponsor: UNICANCER
In heavily pretreated patients with ABC, treatment with EC resulted in an encouraging CBR of 79.5% and PFS of 16.4 Trial completion date: Dec 2023 --> Dec 2024
- | Halaven (eribulin mesylate) / Eisai, Kaitanni (cadonilimab) / Akesobio
New P2 trial, Monotherapy, Metastases: Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov) - Jan 11, 2024
P2, N=128, Not yet recruiting, Sponsor: Shengjing Hospital
- |||| TQB2930 / Sino Biopharm
New P1/2 trial, Combination therapy, Monotherapy, Metastases: A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov) - Jan 11, 2024
P1/2, N=89, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | Halaven (eribulin mesylate) / Eisai
Journal: Eribulin promotes proliferation of CD8 T cells and potentiates T cell-mediated anti-tumor activity against triple-negative breast cancer cells. (Pubmed Central) - Jan 8, 2024
Eribulin promoted CD8 T cell proliferation, repressed effector T cell differentiation, and harnessed T cell-mediated anti-tumor effects. These mechanisms may be one of the cues that eribulin can improve the immunological status of tumor-bearing hosts.
- | Ibrance (palbociclib) / Pfizer, Halaven (eribulin mesylate) / Eisai
Preclinical, Journal: Doublet and Triplet Combinations of Eribulin, Fulvestrant, and Palbociclib in Preclinical Breast Cancer Models. (Pubmed Central) - Jan 6, 2024
These mechanisms may be one of the cues that eribulin can improve the immunological status of tumor-bearing hosts. Results show complex synergistic interactions between eribulin, fulvestrant, and palbociclib, and point to a particularly robust synergy when combining all three drugs.
- || Halaven (eribulin mesylate) / Eisai, eribulin liposomal (E7389-LF) / Eisai, Opdivo (nivolumab) / Ono Pharma, BMS
P2 data, Journal, Combination therapy, PD(L)-1 Biomarker: Phase 2 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort. (Pubmed Central) - Jan 5, 2024
Results show complex synergistic interactions between eribulin, fulvestrant, and palbociclib, and point to a particularly robust synergy when combining all three drugs. E7389-LF 2.1mg/m2 in combination with nivolumab 360mg Q3W showed notable antitumor activity as second-line therapy for SCLC; no new safety signals were observed compared to either agent as monotherapy.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer (clinicaltrials.gov) - Jan 3, 2024
P1/2, N=106, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
E7389-LF 2.1mg/m2 in combination with nivolumab 360mg Q3W showed notable antitumor activity as second-line therapy for SCLC; no new safety signals were observed compared to either agent as monotherapy. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Combination therapy, IO biomarker: EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (clinicaltrials.gov) - Dec 31, 2023
P2, N=30, Recruiting, Sponsor: Australia New Zealand Gynaecological Oncology Group
- ||| paclitaxel / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC). (clinicaltrials.gov) - Dec 31, 2023
P3, N=168, Recruiting, Sponsor: Shanghai Yizhong Pharmaceutical Co., Ltd.
- | Enrollment open, Metastases: ORIENTA: Organoid-based Functional Precision Therapy for Advanced Breast Cancer (clinicaltrials.gov) - Dec 29, 2023
P2, N=252, Recruiting, Sponsor: Guangdong Provincial People's Hospital
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Not yet recruiting --> Recruiting
- || Review, Journal: HER2-targeted therapies for salivary gland cancers. (Pubmed Central) - Dec 25, 2023
Anti-HER2 treatment strategy is emerging as potentially effective in selected HER2 overexpressing SGCs. However, prospective and multicentric clinical trials are needed to evaluate the efficacy of these therapeutic regimens within larger cohorts and to assess the most appropriate treatment sequence strategy.
- || Inlyta (axitinib) / Pfizer, figitumumab (CP-751,871) / Novartis, Halaven (eribulin mesylate) / Eisai
Review, Journal, IO biomarker: Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors. (Pubmed Central) - Dec 23, 2023
Definitive radiotherapy appears to be a promising therapeutic modality. Since standards for the treatment of advanced and metastatic diseases are not available, further investigation of novel agents is necessary.
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Monotherapy, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Dec 20, 2023
P3, N=302, Active, not recruiting, Sponsor: AstraZeneca
Since standards for the treatment of advanced and metastatic diseases are not available, further investigation of novel agents is necessary. Trial completion date: Dec 2023 --> Dec 2024
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J, Votrient (pazopanib) / Novartis, BeiGene, Halaven (eribulin mesylate) / Eisai
Journal: Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database. (Pubmed Central) - Dec 20, 2023
The present study demonstrated the potential of tailored therapy guided by mutation profiles established by comprehensive genomic profiling testing in optimizing second-line chemotherapy for STS. The findings of this study will hopefully contribute some valuable insights into enhancing STS treatment strategies and outcomes.
- | Halaven (eribulin mesylate) / Eisai
Journal: Dedifferentiated liposarcoma with heterologous rhabdomyosarcomatous differentiation in the bone marrow. (Pubmed Central) - Dec 17, 2023
He underwent 3 cycles of eribulin and subsequently developed complications of his increasingly aggressive liposarcoma...While exceedingly rare, it is possible for liposarcoma to metastasize to the bone marrow and cause rapid progression to death. In patients with high-grade liposarcoma, new cytopenia, leukocytosis, elevated granulocyte colony stimulating factor, and/or leukoerythroblasosis on peripheral smear should prompt bone marrow biopsy for early detection of this rare disease entity.
- |||||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Enrollment open, Metastases: DESTINY Breast Respond HER2-low Europe (clinicaltrials.gov) - Dec 6, 2023
P=N/A, N=1350, Recruiting, Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
In patients with high-grade liposarcoma, new cytopenia, leukocytosis, elevated granulocyte colony stimulating factor, and/or leukoerythroblasosis on peripheral smear should prompt bone marrow biopsy for early detection of this rare disease entity. Not yet recruiting --> Recruiting
- | Yutuo (zimberelimab) / Arcus Biosci, Gilead, Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Combination therapy, Metastases: An exploratory study on the first-line treatment of advanced unresectable soft tissue sarcoma with zimberelimab administered in combination with anlotinib and eribulin (EUDRACT) - Dec 5, 2023
P2, N=30, Recruiting, Sponsor: Sanhuan Cancer Hospital, Chaoyang District, Beijing; Sanhuan Cancer Hospital
Not yet recruiting --> Recruiting .
- || Halaven (eribulin mesylate) / Eisai
Clinical data, Journal, HEOR, Real-world evidence, Real-world, Metastases, Immuno-oncology: Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody-Drug Conjugate Therapy. (Pubmed Central) - Nov 29, 2023
In patients with TNBC, median rwPFS and OS from eribulin initiation were 12.0 months (95% CI, 8.8-NE) and 18.3 months (95% CI, 14.9-NE), respectively. These real-world data provide evidence for the clinical effectiveness outcomes of eribulin treatment among MBC patients previously treated with an IO or ADC.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Enrollment closed, Combination therapy, Metastases: Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer (clinicaltrials.gov) - Nov 29, 2023
P1/2, N=106, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
These real-world data provide evidence for the clinical effectiveness outcomes of eribulin treatment among MBC patients previously treated with an IO or ADC. Suspended --> Active, not recruiting
- || Halaven (eribulin mesylate) / Eisai, Opdivo (nivolumab) / Ono Pharma, BMS
P1/2 data, Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16). (Pubmed Central) - Nov 27, 2023
P1/2
Suspended --> Active, not recruiting Nivolumab plus eribulin showed promising efficacy and tolerable safety in previously treated HER2-
- || datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Review, Journal, Metastases: TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. (Pubmed Central) - Nov 27, 2023
Despite recent treatment advances, the prognosis for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) remains poor. Approximately 600 patients will be randomized 1:1 to Dato-DXd 6
- | Halaven (eribulin mesylate) / Eisai
Journal, IO biomarker: Eribulin is an immune potentiator in breast cancer that upregulates human leukocyte antigen class I expression via the induction of NOD-like receptor family CARD domain-containing 5. (Pubmed Central) - Nov 22, 2023
The eribulin and TCR-T combined therapy model revealed that eribulin and immunotherapy using TCR-T cells has a synergistic effect. In summary, eribulin increases the expression of HLA class 1 via HLA class 1 transactivatior NLRC5 and eribulin combination with immunotherapy can be effective for the treatment of breast cancer.
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Trial suspension, Combination therapy, Metastases: Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer (clinicaltrials.gov) - Nov 22, 2023
P1/2, N=106, Suspended, Sponsor: National Cancer Institute (NCI)
In summary, eribulin increases the expression of HLA class 1 via HLA class 1 transactivatior NLRC5 and eribulin combination with immunotherapy can be effective for the treatment of breast cancer. Recruiting --> Suspended
- |||||||| paclitaxel / Generic mfg.
New P3 trial, Metastases: Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC). (clinicaltrials.gov) - Nov 22, 2023
P3, N=168, Recruiting, Sponsor: Shanghai Yizhong Pharmaceutical Co., Ltd.
- || Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Trial primary completion date: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (clinicaltrials.gov) - Nov 18, 2023
P2, N=57, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Suspended Trial primary completion date: Aug 2023 --> Aug 2024
- ||||||| Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
Trial completion, Trial completion date, Trial primary completion date, Metastases: TROPiCS-02: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (clinicaltrials.gov) - Nov 18, 2023
P3, N=543, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Aug 2023 --> Aug 2024 Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> Oct 2023 | Trial primary completion date: Oct 2024 --> Oct 2023
- ||| ipatasertib (RG7440) / Roche
Trial completion, Phase classification, Combination therapy, Metastases: PATHFINDER: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov) - Nov 15, 2023
P2, N=54, Completed, Sponsor: MedSIR
Active, not recruiting --> Completed | Trial completion date: Oct 2024 --> Oct 2023 | Trial primary completion date: Oct 2024 --> Oct 2023 Active, not recruiting --> Completed | Phase classification: P2a --> P2
- | Halaven (eribulin mesylate) / Eisai
Journal: Radiation-Recall-Dermatitis nach Eribulinmesylat. (Pubmed Central) - Nov 10, 2023
Active, not recruiting --> Completed | Phase classification: P2a --> P2 No abstract available
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Votrient (pazopanib) / Novartis, BeiGene, Halaven (eribulin mesylate) / Eisai
Biomarker, Journal, Metastases: Optimal Prognostic Factors for Metastatic and Inoperable Sarcomas Treated With Pazopanib, Eribulin, and Trabectedin. (Pubmed Central) - Nov 4, 2023
Performance status scores and tumor response were significantly associated with patient prognosis. Therefore, regardless of age, sex, primary tumor location, adverse effects, and history of doxorubicin and radiation therapy, use of cutting-edge drugs, such as pazopanib, eribulin, and trabectedin, may be advantageous in patients with advanced sarcomas, if their drug response and performance status scores are good.
- Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Spatial immune correlates of response to eribulin and pembrolizumab in metastatic triple negative breast cancer (mTNBC) on the ENHANCE1 trial (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1859;
The tumor microenvironment on patient samples obtained before one or more lines of therapy prior to enrollment on study are not predictive of response to treatment. Further characterization of the TME via quantitative immunofluorescence is ongoing.
- Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Phase II Trial of Combination of Atezolizumab, Cobimetinib and Eribulin (ACE) or Atezolizumab and Eribulin (AE) in patients with metastatic inflammatory breast cancer (IBC): Clinical data of both cohorts (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1744;
The response profile of the triple combination demonstrated promise, and suggests that MEK inhibition may warrant further investigation as a strategy in metastatic IBC in a larger sample size. However, there does not appear to be synergy between atezolizumab and eribulin without the addition of targeted therapy.
- Halaven (eribulin mesylate) / Eisai
The effect of eribulin treatment for patients with HER2-low breast cancer (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1739;
Further study of this mechanism through basic research is important. Also, assessment of HER2 from primary tumor may be more useful than recurrent specimen.
- Halaven (eribulin mesylate) / Eisai
Eribulin Induces Chromosomal Instability and Enhances cGAS Expression in the Nucleus of Triple-Negative Breast Cancer. (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1322;
These findings contribute to our understanding of ERI's effects on the innate immune response in triple-negative breast cancer, potentially paving the way for improved therapeutic strategies. The differences in intensity scores between GroupP and GroupE in the immunostaining of cGAS High cGAS expression in Group E correlated with increased pCR rates (p=0.0375) , while no such correlation was observed in Group P (p=0.2983).
- Five years and counting: A case of a 47-year-old female with De Novo Metastatic HER2 positive disease on multiple lines of treatment (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1280;
Disease then progressed to the contralateral breast, given 6 cycles of Ado Trastuzumab Emtansine with partial response followed by modified radical mastectomy of the right and toilet total mastectomy of the left breast...Patient was then given 5 cycles of Trastuzumab with Eribulin...The patient will continue to receive Fam-Trastuzumab Deruxtecan-nxki until disease progression and/or unacceptable toxicity...Ongoing research continues to explore new therapeutic approaches and strategies to further improve outcomes for individuals with metastatic HER2-positive breast cancer. This is truly an exciting time for cancer research because what used to be a very deadly disease is now becoming something that we are able manage.
- Halaven (eribulin mesylate) / Eisai, sabizabulin (VERU-111) / Veru Inc, Valeo Pharma
A novel stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor targeting microtubules (60c) is effective against taxane-resistant, metastatic breast cancer (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1121;
In vivo, 60c therapy significantly suppressed primary tumor growth and lung metastasis in an orthotopic MDA-MB-231-TxR xenograft model without gross toxicity, and with equivalent efficacy to combrestatin A4 phosphate (CA-4P), another CBSI in clinical trials. In the taxane-refractory HCI-10-Luc2 PDX model, 60c significantly suppressed both the growth of the primary tumor (by ~3.5 fold) and the expansion of pre-established axillary metastases (by ~26 fold) whereas paclitaxel had no effect.
- Halaven (eribulin mesylate) / Eisai
Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II study (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1104;
P2
Table. Summary of efficacy outcomes
- Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
Unmet clinical need in patients with pre-treated hormone receptor-positive/HER2-negative (HR+/HER2 (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_1092;
Eribulin use in ? 2L had a mPFS of 4.6
- Halaven (eribulin mesylate) / Eisai
Immune related cell fraction in peripheral blood and outcomes of advanced breast cancer patients treated with Eribulin (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_907;
In the current study, Tregs in the peripheral blood of breast cancer patients significantly decreased after eribulin treatment, suggesting that eribulin may improve the immune microenvironment by suppressing immunosuppressive cells in cancer, including Tregs. In addition, the CD4-CD25-FoxP3+ cell fraction may serve as a biomarker for eribulin therapy, and further studies are needed to elucidate the details, including analysis of the constituent cells within the fraction.
- Halaven (eribulin mesylate) / Eisai
Platelet-to-lymphocyte ratio in patients with metastatic breast cancer treated with eribulin. (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_901;
Multivariate analysis revealed low albumin-bilirubin grade (P < 0.001), high hemoglobin (P < 0.01), and low PLR (P < 0.05) as independent factors of longer OS after eribulin administration. Low PLR, anemia, and liver dysfunction might be factors associated with prolonged OS in patients with recurrent/stage IV BC on eribulin therapy, which could be clinically useful, as their evaluation requires neither new equipment nor invasive testing.
- Cosela (trilaciclib) / G1 Therap
Patients with metastatic triple-negative breast cancer who receive trilaciclib prior to cytotoxic chemotherapy exhibit improved survival after receiving subsequent anticancer therapy (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_807;
P2, P3
Improved OS in pts receiving trilaciclib may be associated with protection of hematopoietic stem and progenitor cells and formation of a memory T-cell pool, which is critical for long-term immune surveillance and in eliciting rapid recall responses. OS will be evaluated in pts with mTNBC in the ongoing phase 3 trial of trilaciclib prior to GCb (PRESERVE 2; NCT04799249) and phase 2 trial of trilaciclib prior to sacituzumab govitecan (NCT05113966).
- Halaven (eribulin mesylate) / Eisai
Prospective study on eribulin efficacy in advanced and metastatic breast cancer: changes in TGF-? compared to other standard chemotherapy agents (KBCSG-TR 2018, POTENTIAL) (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_799;
OS will be evaluated in pts with mTNBC in the ongoing phase 3 trial of trilaciclib prior to GCb (PRESERVE 2; NCT04799249) and phase 2 trial of trilaciclib prior to sacituzumab govitecan (NCT05113966). Methods Patients with HER2-negative recurrent / metastatic breast cancer (MBC) were prospectively enrolled from 23 breast cancer centers in Japan, if they had not previously used E, had received two or fewer prior chemotherapy regimens, and were scheduled to start either E, capecitabine, S-1 or paclitaxel (
- Halaven (eribulin mesylate) / Eisai
Retrospective analysis on therapeutic efficacy and predictive indicators of eribulin plus anti-angiogenic drugs for metastatic breast cancer (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_793;
Other factors such as prior non-taxane resistance, grade 3-4 neutropenia occurrence after treatment, and combined anti-angiogenic therapy can be used as biomarkers for predicting treatment efficacy. The adverse events are manageable and the safety of combined therapy can be guaranteed.
- Halaven (eribulin mesylate) / Eisai
Real-world outcomes of systemic therapy for advanced triple-negative breast cancer: a tertiary centre experience (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_617;
Eribulin was the most common choice in 3rd line and 4th lines (37.4% and 30%, respectively)...Table 1. ORR and PFS to First, second, third and fourth-line systemic treatment.
- Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Preliminary results of a phase I dose escalation study of eribulin in combination with copanlisib in patients with metastatic triple negative breast cancer (TNBC) (Hall 2-3) - Nov 4, 2023 - Abstract #SABCS2023SABCS_499;
P1/2
These data indicate that E+C at DL1 is a well-tolerated regimen warranting further investigation. The study is actively enrolling patients to the phase II study.
- BB-1701 / BlissBio, Eisai
Report on Cohort Expansion of Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of BB-1701 in Patients with Locally Advanced/Metastatic HER2 Low Breast Cancer (Hall 1) - Nov 4, 2023 - Abstract #SABCS2023SABCS_276;
monoclonal anti-HER2 antibody with the same sequence as trastuzumab and eribulin linked together by a cathepsin-cleavable valine-citrulline linker...One patient who achieved PR was previously progressed on sacituzumab govitecan... BB-1701 has demonstrated promising preliminary antitumor activity in HER2 low breast cancer including patients who received prior anti-HER2 ADCs, and a manageable safety profile.
- datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer: Results from TROPION-Breast01 (Hall 1) - Nov 4, 2023 - Abstract #SABCS2023SABCS_246;
P3
These data support Dato-DXd as a potential new therapeutic option for pts with inoperable or metastatic HR+/HER2? BC who have received 1?2 prior lines of CT.
- | balixafortide (POL 6326) / Spexis
Trial termination, Combination therapy, Metastases: FORTRESS: Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Nov 1, 2023
P3, N=432, Terminated, Sponsor: Spexis AG
BC who have received 1?2 prior lines of CT. Active, not recruiting --> Terminated; The study was halted early due to failure to meet the primary endpoint.